Flag of the European Union EU Clinical Trials Register Help

Clinical trials for MASS syndrome

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    574 result(s) found for: MASS syndrome. Displaying page 9 of 29.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2007-003372-18 Sponsor Protocol Number: NERI-AS001-07 Start Date*: 2007-12-03
    Sponsor Name:ABIOGEN PHARMA
    Full Title: A randomised, double-blind, placebo controlled study to assess the safety and the efficacy of neridronate 100 mg - 4 i.v. infusions in a course of 10 days treatment - in patients with algodystrophi...
    Medical condition: Algodystrophic Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028395 Musculoskeletal and connective tissue disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-001060-36 Sponsor Protocol Number: MTE08 Start Date*: 2008-09-05
    Sponsor Name:Acrux Pharma Pty Ltd
    Full Title: A Phase III open-label titration trial to evaluate the effectiveness and safety of different doses of a dermal application of Testosterone MD-Lotion® (cutaneous solution) in hypogonadal men
    Medical condition: Male Hypogonadism
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021011 Hypogonadism male LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (Completed) DE (Completed) SE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2018-002365-19 Sponsor Protocol Number: 2 Start Date*: 2018-08-22
    Sponsor Name:Line Velling Magnussen
    Full Title: Muscle strength and -mass after bariatric surgery - a possible effect of testosterone replacement therapy? Randomized, placebo-controlled and double-blinded study
    Medical condition: General aim To investigate the effect and clinical relevance of testosterone therapy combined with exercise and diet counselling in hypogonadal men undergoing bariatric surgery. Objectives To eval...
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-006445-41 Sponsor Protocol Number: CTSSTS1010207V2 Start Date*: 2012-01-28
    Sponsor Name:HEALTH RICERCAE SVILUPPO SRL
    Full Title: The irreversibility of hemorrhagic shock treatment with anti-opiod neuropeptide
    Medical condition: Mortality of hemorrhagic shock grade 2 and 3 is from 50 to '80% in the first 24 hours, and morbidity and mortality betrayed is to 7 to 8 days of' 90% for Acute Respiratory Distress Syndrome and / o...
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10049771 Shock haemorrhagic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-002306-19 Sponsor Protocol Number: Hyp Hop Start Date*: 2010-02-10
    Sponsor Name:University of Rochester
    Full Title: Double-blind, placebo-controlled, parallel group, phase III study comparing dichlorphenamide vs. placebo for the treatment of periodic paralysis
    Medical condition: Patients with hyperkalemic (HYP) and hypokalemic (HOP) periodic paralysis.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10016208 Familial periodic paralysis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-003727-23 Sponsor Protocol Number: RRK3563 Start Date*: 2008-12-16
    Sponsor Name:University Hospital Birmingham NHS Foundation Trust
    Full Title: Does phosphate binding with sevelamer carbonate improve cardiovascular structure and function in patients with early chronic kidney disease?
    Medical condition: Chronic kidney disease stage 3 (eGFR 30-59 ml/min/1.73m2)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-004481-13 Sponsor Protocol Number: NN8022-1807 Start Date*: 2006-10-18
    Sponsor Name:Novo Nordisk A/S [...]
    1. Novo Nordisk A/S
    2. Novo Nordisk A/S
    Full Title: Effect of liraglutide on body weight in obese subjects without diabetes A 20-week randomised, double-blind, placebo-controlled, six armed parallel group, multi-centre, multinational trial with an o...
    Medical condition: obesity
    Disease: Version SOC Term Classification Code Term Level
    9.0 10012601 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed) CZ (Completed) FI (Completed) DK (Completed) NL (Completed) BE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000995-13 Sponsor Protocol Number: DECODE-CKD Start Date*: 2022-01-26
    Sponsor Name:Department of Cardiology, Herlev and Gentofte hospital
    Full Title: A 6-Month, Randomized, Double-Blind Study to Evaluate the Effect of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease (DECODE-CKD)
    Medical condition: Chronic kidney disease
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-001275-38 Sponsor Protocol Number: ADG20001 Start Date*: 2006-07-20
    Sponsor Name:GlaxoSmithKline R&D
    Full Title: A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group, Placebo-Controlled, Study To Evaluate Efficacy, Safety And Tolerability Of Oral GW677954 Capsules (2.5, 5, 10, 15 And 20 Mg On...
    Medical condition: Subjects between the ages of 18 and 70 years with T2DM who are diet and/or exercise treated or receiving stable metformin monotherapy will be recruited
    Disease: Version SOC Term Classification Code Term Level
    7.1 10052066 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) LV (Completed)
    Trial results: View results
    EudraCT Number: 2008-005506-40 Sponsor Protocol Number: CLDE225B2203 Start Date*: 2009-08-06
    Sponsor Name:Novartis Pharma
    Full Title: A double-blind, randomized, vehicle-controlled Proof of Concept (PoC) study, to evaluate the safety, local tolerability, pharmacokinetics and pharmacodynamics of multiple topical administrations of...
    Medical condition: Gorlin syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2015-002895-26 Sponsor Protocol Number: PrEP-CS-001 Start Date*: 2015-09-08
    Sponsor Name:hVIVO Services Limited
    Full Title: A Phase II, Repeated Dose, Double-Blinded, Randomised, Controlled Study to Examine the Prophylactic Efficacy, Safety and Tolerability of PrEP-001 in Healthy Subjects Subsequently Challenged with In...
    Medical condition: Influenza A/Perth/16/2009(H3N2) Virus
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-003463-97 Sponsor Protocol Number: RVL-VRL01 Start Date*: 2021-09-24
    Sponsor Name:Revelation Biosciences, Inc.
    Full Title: A Phase IIb Study Assessing Prophylactic Efficacy of Intranasal REVTx-99 in an H3N2 Influenza Challenge Model in Healthy Subjects.
    Medical condition: Influenza A
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10022000 Influenza PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000917-38 Sponsor Protocol Number: CBPR277X2101 Start Date*: 2011-09-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A first–in-human study to evaluate safety and tolerability of repeated topical administrations of BPR277 ointment in healthy volunteers, and safety, tolerability, and preliminary efficacy of multip...
    Medical condition: Part 2: Atopic Dermatitis (AD) Part 3: Netherton Syndrome (NS)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004858 10003639 Atopic dermatitis LLT
    14.1 10010331 - Congenital, familial and genetic disorders 10062909 Netherton's syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000962-14 Sponsor Protocol Number: CCM-RNT-202101 Start Date*: 2021-07-02
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: A Monocenter, Open Label Study to Evaluate the Safety and Efficacy of Daratumumab in Combination with Standard Background Therapy in Participants with Moderate to Severe Systemic Lupus Erythematosus
    Medical condition: Systemic Lupus Erythematosus
    Disease: Version SOC Term Classification Code Term Level
    21.1 10028395 - Musculoskeletal and connective tissue disorders 10042945 Systemic lupus erythematosus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-004019-29 Sponsor Protocol Number: CRACCA-2019 Start Date*: 2021-07-15
    Sponsor Name:Dipartimento di Medicina-DIMED, università di Padova
    Full Title: Medical combination therapy with retinoic acid and cabergoline in ACTH-secreting pituitary adenoma: a prospective and randomized study.
    Medical condition: Cushing's disease in patients in whom pituitary surgery has not been curative or in situations where it is contraindicated or refused by patient.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10011651 Cushing's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-019395-73 Sponsor Protocol Number: CPJMR0012201 Start Date*: 2010-09-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A 2-week single-blind, randomized, 3-arm proof of concept study of the effects of AIN457 (anti-IL17 antibody), ACZ885 (canakinumab, anti-IL1b antibody), or corticosteroids in patients with polymyal...
    Medical condition: polymyalgia rheumatica
    Disease: Version SOC Term Classification Code Term Level
    14.0 10028395 - Musculoskeletal and connective tissue disorders 10036099 Polymyalgia rheumatica PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-005482-12 Sponsor Protocol Number: GLP-1-2012-01 Start Date*: 2013-04-15
    Sponsor Name:University College Dublin
    Full Title: The effect of glucagon-like-peptide 1 (GLP-1) analogues on inflammation in humans with diabetic kidney disease.
    Medical condition: Diabetic Kidney Disease
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004857 10012687 Diabetic renal disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004523-19 Sponsor Protocol Number: TIP0305 Start Date*: 2008-02-08
    Sponsor Name:Área de Trasplante y Terapia Celular - Hospital Central de Asturias
    Full Title: Phase II clinical trial to evaluate the efficacy and safety in the use of pancreatic islets cells from cadaver donors for the treatment of Type-I Diabetes Mellitus in renal transplant patients.
    Medical condition: Type-I Diabetes Mellitus in renal trasplant patients
    Disease: Version SOC Term Classification Code Term Level
    8.1 10061835 pt
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003060-40 Sponsor Protocol Number: TICSI Start Date*: 2017-01-17
    Sponsor Name:University of Oxford, Clinical Trials and Research Governance
    Full Title: Targeting Iatrogenic Cushing’s Syndrome with 11β-hydroxysteroid dehydrogenase type 1 Inhibition
    Medical condition: Adverse effects of prescribed glucocorticoid therapy
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004860 10068501 Cushing's syndrome, steroid-induced LLT
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001108-35 Sponsor Protocol Number: NRA 6290010 Start Date*: 2006-07-03
    Sponsor Name:Clinic of University of Wuerzburg
    Full Title: CHANGES OF LEFT VENTRICULAR MASS AND CARDIAC FUNCTION IN PATIENTS WITH ACTIVE ACROMEGALY DURING TREATMENT WITH THE GROWTH HORMONE RECEPTOR ANTAGONIST PEGVISOMANT: AN OPEN-LABELLED, PROSPECTIVE STUDY
    Medical condition: Somavert (Pegvisomant) is approved for the treatment of acromegalic patients who have had an inadequate response to surgery and/or radiation therapy and/or other medical therapy as Somatostatin Ana...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10061835 llt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue Jun 17 12:17:58 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA